Medwise.ai uses Artificial Intelligence (AI) to answer questions for clinicians faster than they can respond to. It asserts that currently, doctors cannot keep up with the latest research evidence making them unable to provide the best care for their patients. It also points out that health care providers in the UK, such as the NHS, are losing £5 billion every year due to the lack of adoption of evidence-based best practices. Medwise.ai aims to change this by utilising the latest transformer-based neural networks and Natural Language Processing (NLP) technologies to extract answers from multiple sources and support clinicians to make the best decisions for patients. Medwise.ai argues that unlike traditional search engines that provide a user with a list of websites or documents, medwise.ai's portal and app provide bite-sized, actionable, and evidence-based answers extracted from trusted sources. The company is envisaging an exit through an acquisition by a publishing company, an Electronic Health Records (EHR) company, or a pharmaceutical company.
days to go:
Expired
investment:
£666,000
Miappi helps brands amplify their social content to increase audience engagement and reach. We combine social feeds and user generated content (e.g. #tags) to give a unified view of a brand’s social footprint. Our dashboard gives full design, curation and moderation resulting in beautiful applications on websites, mobile apps, DOOH and event screens. Existing clients include Sony Music, Bauer Media, Diageo and Exterion with a substantial (£1m+) pipeline of further prospects.
days to go:
Expired
investment:
£264,355
Already working with clients including Puma, British Airways, Three and Sony Music, Miappi’s SaaS platform unifies social media into a social hub. Since our last successful pitch on Angels Den in April 2015, with an experienced management team, Miappi has already achieved significant traction. Our monthly recurring revenue has been growing on average 50% month on month since August 2015 and our sign-up growth has been averaging 30% in the same period. Major channel partners are already agreed and are delivering revenue that will grow rapidly in 2016. “Really simple, really impactful” Director of Brand & Communications Three
days to go:
Expired
investment:
£599,476
Providing survey researchers profiled access to every mobile smart phone and tablet user. Meaning researchers are no longer limited to accessing recruited panelists on the phone or via the web, and can finally interact with 18-35 yr olds.
A location based user that is acquired at a cost of £0.50, is profiled and then sold on for an estimated lifetime value in excess of £10.
days to go:
Expired
investment:
£30,000
Mous is a fashion/tech brand that’s disrupting the $37billion phone accessories category. Mous has had huge exposure already for their latest ergonomic and slim iPhone 6 case that holds and retracts headphones, solving very real shopper problems. The trends of wireless earphones present a real opportunity for Mous in the future.
days to go:
Expired
investment:
£41,580
On NightZookeeper.com, children create their magical animals that come to life (e.g. Tamagotchis), which teachers then use to deliver interactive lesson content. The children’s work is then sent to a teacher dashboard and automatically assessed. As well as building brand awareness and reach, the website has generated £100,000 in recurring annual subscriptions during the past 12 months.
days to go:
Expired
investment:
£585,368
Novai is a UK biotechnology company, developing and commercialising transformational technology in ophthalmology. The company's initial focus is on ophthalmic disorders such as glaucoma and AMD (Age-related Macular Degeneration). Novai argues that current clinical endpoints lack early disease biomarkers to objectively detect and measure cell health and response to treatment in the retina. Novai asserts that its proprietary biological marker, DARC (Detection of Apoptosis in Retinal Cells), combined with its bespoke and patented Artificial Intelligence (AI) aided algorithm, allows, for the first time in vivo, identification of cellular-level disease activity in the retina. Novai stresses that DARC can also predict disease progression, allowing for enrichment of clinical trial cohorts. The company anticipates an exit via licensing of its biomarker business to a Contract Research Organisation (CRO), an Initial Public Offering (IPO) following a successful phase 3 trial of the diagnostic platform, or trade sale to a strategic pharmaceutical company.
days to go:
Expired
investment:
£1,314,967
Orbitil have created a fun and easy project management program for comparing analytics and business intelligence. They provide a large variety of tools to help business leaders make better tactical decisions based on confirmed data.
days to go:
Expired
investment:
£133,414
Ordoo believes that in 3 years everyone will order food and drink via digital channels. They’re determined to transform the way we order by creating exceptional mobile ordering experiences. As a result, Ordoo has built a mobile ordering app that saves busy people time ordering food and drink. Ordoo plans to lead the transformation to digital ordering and help our partner venues increase their profitable sales. Their mobile ordering platform has proven to increase customer frequency by 3x/month, average spend by 13% and encourage word of mouth referrals. Since launching in January 2016, they’ve processed 35k+ orders, signed up 19k+ users and partnered with 75+ venues in 3 cities.
days to go:
Expired
investment:
£50,000
Pinga is an on-demand local delivery service designed for communities to directly help each other via an app. A 'Tasker' is a person who requires something and a 'Runner' is able to acquire it. Goods and delivery fees can easily and quickly be negotiated through the app with delivery times typically being around 15 minutes, far cheaper and quicker than competitors such as Amazon Prime.
days to go:
Expired
investment:
£135,001
